6th Annual Pharma Marketing & Branding Excellence

Jacob Fleming Group25 - 26 January 2011, Milan, Italy.
Recently, behaviors of pharmaceutical marketing landscape, which includes health care providers, patients, and consumers are changing. Pharma companies are now favoring marketing through new media technologies like mobile-Web integration and online interactivity.

Following five successful annuals, Jacob Fleming Group invites you to the 6th Annual Pharma Marketing & Branding Excellence. Jacob Fleming Group has gathered worldwide Pharma marketing specialists who will share their knowledge with you. Hear them speak about the most powerful marketing strategies and network face-to-face.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from pharmaceutical industry. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Senior Vice President, Global Marketing, Bayer Healthcare, Germany
  • Head of Marketing, Specialty Care Business Unit, Pfizer, Finland
  • Director Strategic Marketing, Member of the Executive Committee, Abbott, Switzerland
  • Head of Marketing Scandinavia, UCB, Norway
  • Associate Director, EMEA Marketing, Baxter, Switzerland
  • Vice President, Franchise & Global Marketing Operations, Sanofi Pasteur, France
  • Founder and managing director of Webicina.com, Author of Scienceroll.com, University of Debrecen Medical School and Health
  • Senior Marketing Director, Pfizer, UK
  • Executive Director, Global Marketing Excellence, Johnson & Johnson, UK

Key topics:

  • Case studies from top pharmaceutical companies on how to target the most interesting segments through different channels
  • Understand, how to utilize the potential of mobile marketing & achieve greater brand interactivity and immediate response metrics for your brands.
  • Real life case studies on how to expand “traditional” e-detailing beyond its current limitations
  • Working case studies on how to develop and effective social media strategy
  • Find out how to achieve branding excellence in highly competitive market place
  • Experiences of top pharmaceutical companies on how to overcome barriers for effective closed loop marketing
  • Case studies on how to built sustainable brand equity in a commoditized market
  • Real life case studies on how to successfully select the most suitable brands for e-communication

Who should attend:
Senior Vice presidents, Vice presidents, Senior Executives, Global Heads, Heads, International Directors, Senior Directors, Directors, Senior Managers, Managers of: Marketing & Sales, Marketing, Marketing excellence, CRM, e-Marketing, Branding, Communication, Business Unit Directors, Strategic Planning, Commercial operations, Strategic Marketing, Brand management, Product Directors, Key Accounts, Advertising, Market research, Business Intelligence.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6th-annual-marketing-branding-excellence?partner=worldpharmanewsMB

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...